Skip to content
Screener

CapEx at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$1.94M-27.6%
LON
LeonaBio, Inc.LONA
$28K-15.2%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$473K-31.9%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$4.72M+179%
Immunome logo
ImmunomeIMNM
$2.18M+140%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$0

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$572.13M+18.3%
Enterprise value$493.43M+30.3%
P/S6.4×+5.1×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: Arvinas’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 5:18 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033669
(dollars in millions)For the Three Months Ended March 31, 2026For the Three Months Ended March 31, 2025
Purchases of marketable securities(178.9)(119.6)
Maturities of marketable securities165.0189.5
Sales of marketable securities28.9
Purchases of property, equipment and leasehold improvements(1.3)(0.4)
Net cash provided by investing activities13.769.5
Cash flows from financing activities:
Repayments of long-term debt(0.1)(0.1)
Net cash used in financing activities(0.1)(0.1)

Item 1. Financial Statements (Unaudited)

FAQ

What is Arvinas's capex?
Arvinas (ARVN) reported capex of $1.3M in Q1 2026.
How has Arvinas's capex changed year-over-year?
Arvinas's capex increased by 225.0% year-over-year, from $400K to $1.3M.
What is the long-term trend for Arvinas's capex?
Over 4 years (2021 to 2025), Arvinas's capex has grown at a -20.3% compound annual growth rate (CAGR), from $4.7M to $1.9M.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.

Ask your AI about Arvinas's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude